Enlivex Ltd. Form 6-K Summary
Business Context and Reporting Period
Enlivex Ltd., an Israeli foreign private issuer, furnished this Form 6-K in September 2026. The filing identifies unaudited condensed consolidated financial statements and the related Operating and Financial Review and Prospects for the three- and six-month periods ended June 30, 2026 and 2025, together with balance sheet information as of June 30, 2026 and December 31, 2025.
The filing does not describe Enlivex’s business operations or provide the underlying financial statement figures in the supplied text.
Financial Metrics
- Revenue, operating expenses, net loss, margins, and loss per share: the filing text supplied does not provide clear values.
- Operating, investing, and financing cash flows: the filing text supplied does not provide clear values.
- Cash, cash equivalents, liquidity, debt, and other balance-sheet metrics: the filing text supplied does not provide clear values.
- The detailed unaudited financial statements are furnished as Exhibit 99.1, and the related management discussion is furnished as Exhibit 99.2.
Material Changes Versus the Prior Comparable Period
The filing identifies comparative periods for the three and six months ended June 30, 2025, but the supplied text does not include the comparative results or quantify changes from the prior periods.
Guidance, Outlook, Risks, and Unusual Items
The filing states that an Operating and Financial Review and Prospects is included as Exhibit 99.2. However, the supplied text does not provide management guidance, outlook statements, risk updates, contingencies, liquidity warnings, or unusual items.
The financial statements and related exhibits are incorporated by reference into specified Form S-8, F-3, and F-3MEF registration statements.
Investor Verification Items
- Review Exhibit 99.1 for revenue, expenses, net loss, cash position, debt, operating cash burn, and changes in shareholders’ equity.
- Review Exhibit 99.2 for year-over-year explanations, clinical or operational developments, liquidity outlook, funding needs, and risk disclosures.
- Verify whether the company reported any material changes in cash runway, financing arrangements, share issuance, or contractual obligations.
- Confirm the filing’s stated reporting dates and compare June 30, 2026 balances with December 31, 2025 balances.